Standard BioTools Inc.
LAB
$1.50
$0.074.90%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -11.47% | -3.25% | -6.61% | 65.74% | -12.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -11.47% | -3.25% | -6.61% | 65.74% | -12.93% |
| Cost of Revenue | 1.08% | -11.76% | -19.94% | 67.30% | -29.92% |
| Gross Profit | -21.79% | 45.10% | 55.58% | 64.00% | 8.71% |
| SG&A Expenses | 8.70% | 13.05% | 12.91% | 76.02% | 9.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.00% | 2.80% | -0.48% | 77.41% | -3.52% |
| Operating Income | -21.72% | -9.06% | -5.30% | -99.49% | -10.12% |
| Income Before Tax | -50.91% | 28.04% | -44.18% | -69.53% | -4.08% |
| Income Tax Expenses | -1,130.51% | -1,661.54% | -205.31% | 267.90% | 136.00% |
| Earnings from Continuing Operations | -44.55% | 30.54% | -42.47% | -72.29% | -4.39% |
| Earnings from Discontinued Operations | 40.17% | 22.14% | 83.10% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.77% | 26.81% | 19.04% | -72.29% | -28.29% |
| EBIT | -21.72% | -9.06% | -5.30% | -99.49% | -10.12% |
| EBITDA | -69.40% | -13.71% | -12.59% | -134.39% | -62.96% |
| EPS Basic | -25.10% | 28.42% | 74.12% | 63.31% | 72.67% |
| Normalized Basic EPS | -58.26% | 5.65% | 6.34% | 51.37% | 82.27% |
| EPS Diluted | -25.10% | 28.42% | 74.12% | 64.03% | 73.15% |
| Normalized Diluted EPS | -58.26% | 5.65% | 6.34% | 51.37% | 82.27% |
| Average Basic Shares Outstanding | 2.99% | 2.19% | 28.60% | 369.77% | 369.40% |
| Average Diluted Shares Outstanding | 2.99% | 2.19% | 28.60% | 369.77% | 369.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |